Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
Nonalcoholic fatty liver disease (NAFLD) affects approximately 30% of the population worldwide and includes nonalcoholic fatty liver, nonalcoholic steatohepatitis (NASH), and cirrhosis. Since NAFLD-associated diseases begin with steatosis, the early diagnosis of steatosis helps to prevent the progre...
| الحاوية / القاعدة: | Clinical and Molecular Hepatology |
|---|---|
| المؤلف الرئيسي: | |
| التنسيق: | مقال |
| اللغة: | الإنجليزية |
| منشور في: |
Korean Association for the Study of the Liver
2023-02-01
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | http://e-cmh.org/upload/pdf/cmh-2022-0362.pdf |
| الملخص: | Nonalcoholic fatty liver disease (NAFLD) affects approximately 30% of the population worldwide and includes nonalcoholic fatty liver, nonalcoholic steatohepatitis (NASH), and cirrhosis. Since NAFLD-associated diseases begin with steatosis, the early diagnosis of steatosis helps to prevent the progression of NASH and fibrosis. In addition, more convenient and easily diagnosable serum biomarkers are becoming crucial in disease diagnosis. In this report, we summarize the known serum biomarkers for liver steatosis and provide guidance for their application in clinical practice. |
|---|---|
| تدمد: | 2287-2728 2287-285X |